Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8748382 | RADIUS HEALTH INC | Method of drug delivery for bone anabolic protein |
Oct, 2027
(4 years from now) | |
US8148333 | RADIUS HEALTH INC | Stable composition comprising a PTHrP analogue |
Nov, 2027
(4 years from now) | |
US7803770 | RADIUS HEALTH INC | Method of treating osteoporosis comprising administration of PTHrP analog |
Apr, 2031
(8 years from now) | |
US10996208 | RADIUS HEALTH INC | Abaloparatide formulations and methods of testing, storing, modifying, and using same |
Apr, 2038
(15 years from now) | |
US11255842 | RADIUS HEALTH INC | Methods for detecting neutralizing antibodies to parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHRP) analog |
Jan, 2040
(16 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Apr 28, 2022 |
M | Sep 20, 2024 |
Drugs and Companies using ABALOPARATIDE ingredient
NCE-1 date: April, 2021
Market Authorisation Date: 28 April, 2017
Treatment: Method of treating postmenopausal women with osteoporosis at high risk for fracture.; Use for detecting neutralizing antibodies
Dosage: SOLUTION;SUBCUTANEOUS
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic